Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNG2 | P59768 | 5/20 | 1.00 |
| ▸ | GNB1 | P62873 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.77 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.71 |
| ▸ | MET | P08581 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.67 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.67 |
| ▸ | HGF | P14210 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354288 | 1.00 | GNG2 (1.00) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL3029899 | 0.99 | GNG2 (0.97) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL13021512 | 0.96 | GNG2 (0.92) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL13891732 | 0.93 | GNG2 (0.86) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL13213975 | 0.92 | GNG2 (0.86) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL791019 | 0.92 | GNG2 (0.85) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL29357302 | 0.92 | GNG2 (0.85) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL7765342 | 0.91 | GNG2 (0.84) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL29355106 | 0.91 | GNG2 (0.84) | GNG2GNB1CYP1A2CYP2C9ALOX15 | |
| SCHEMBL10708708 | 0.91 | GNG2 (0.84) | GNG2GNB1CYP1A2CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | claimed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| CN-114008048-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2022-02-01 | — | — | CN | claimed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | claimed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | claimed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | claimed |
| CN-112888696-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2021-06-01 | — | — | CN | claimed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | claimed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | claimed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3510040-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2010-05-27 | — | — | US | claimed |
| EP-2147310-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | University of Rochester (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2009020677-A9 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIV ROCHESTER (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2009020677-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2009-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | GNG2 810/4885GNB1 914/4885CYP1A2 1262/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | GNG2 1035/4885GNB1 899/4885CYP1A2 1596/4885 |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | GNAI1, GNAI3, GNAI2 | GNG2 5/4885GNB1 4/4885CYP1A2 4839/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | GNG2 1402/4885GNB1 892/4885CYP1A2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.